Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis

Multiple Sclerosis Journal

Volumn 20, Issue 13, 2014, Pages 1792-1793

  Van Rossum, J A ^a   Looysen, E E ^a   Daniels, J M A ^a   Killestein, J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FINGOLIMOD; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MONTELUKAST; PREDNISOLONE; STEROID; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ASTHMA; CASE REPORT; DISEASE EXACERBATION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LETTER; MULTIPLE SCLEROSIS; SPIROMETRY; TREATMENT DURATION; WHEEZING; ADD ON THERAPY; DETERIORATION; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; LUNG FUNCTION; OUTCOME ASSESSMENT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ADULT; ASTHMA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84911451694     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514531844     Document Type: Letter

References (5)

1. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
2. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140.
3. Trifilieff A and Fozard JR. Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor. J Pharmacol Exp Ther 2012; 342: 399-406.
4. Voldsgaard A, Koch-Henriksen N, Magyari M, et al. Cardiac and pulmonary effects related to initiation of fingolimod treatment. (Oct 4, 2013).
5. Slade A et al. Effects of oral fingolimod (FTY720) on pulmonary function tests in patients with moderate asthma. Neurology 2010; 74(number 9, supplement 2).